Patients with advanced colorectal cancer receiving combined FOLFOX and bevacizumab have decreased VEGFB-mediated angiogenesis, including reduced myeloid cell-endothelial cell communication through VEGF as identified by scRNA-seq.66 The gene discussed is VEGFA; the disease is colorectal cancer.